

Special Issue

COVID-19 Vaccination Strategies and Perspectives in the United States

Message from the Guest Editors

In the United States, the response to the COVID-19 pandemic has been marked by political and social conflict, with inconsistent health messages from the government, health agencies and the media. As of December 2021, approximately 62% of the US population has been fully vaccinated. However, regional, state, and county vaccination rates are extremely variable, with some states reporting counties with fewer than 20% and greater than 98% of the population vaccinated. Elected officials and public health agencies have used various strategies to encourage residents to become vaccinated, but vaccine hesitancy remains high in some areas. This issue of *Vaccines* focuses on the COVID-19 vaccine experience throughout the United States, with emphasis on vaccine hesitancy and acceptance, strategies to enhance vaccination coverage and promote equity, and the health and social consequences of low vaccination rates. We invite you to share your research, review, or opinion papers in any of these areas, with the hope of bringing more understanding to this ongoing issue and to aid in future vaccine efforts.

Guest Editors

Dr. Leslie Elliott

School of Public Health, University of Nevada, Reno, NV 89557, USA

Dr. Dana Loomis

Plumas County Public Health Agency, Quincy, CA 95971, USA

Deadline for manuscript submissions

closed (15 December 2022)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/107630

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).